{"id":"W2095826876","doi":"10.1016/s1470-2045(09)70334-1","title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1187,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Ipilimumab; Adverse effect; Clinical endpoint; Internal medicine; Melanoma; Clinical trial; Intention-to-treat analysis; Phases of clinical research; Randomized controlled trial; Gastroenterology; Surgery; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03300815461349548,"score_gpt":0.3521155906350885,"score_spread":0.319107436021593,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}